1h Free Analyst Time
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor XIa include protein Z-dependent protease inhibitor.Speak directly to the analyst to clarify any post sales queries you may have.
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) pipeline Target constitutes close to 30 molecules. Out of which approximately 29 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 8, 7, 2, 10 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Hematological Disorders, Genito Urinary System And Sex Hormones, Infectious Disease, Central Nervous System and Immunology which include indications Thrombosis, Venous Thromboembolism, Bleeding And Clotting Disorders, Arterial Thrombosis, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Thromboembolic Disease, Atrial Fibrillation, Deep Vein Thrombosis (DVT), Hemophilia C (Factor XI Deficiency), Venous (Vein) Thrombosis, Acute Ischemic Stroke, Blood Coagulation, Coronavirus Disease 2019 (COVID-19), Inflammation, Ischemic Stroke, Myocardial Infarction, Neurology, Pulmonary Embolism, Sepsis, Stroke and Thromboembolism.
The latest report Coagulation Factor XI - Drugs In Development, 2022, outlays comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)
- The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects
- The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Overview
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Companies Involved in Therapeutics Development
- Alphamab Oncology
- Anthos Therapeutics Inc
- Aronora Inc
- Bayer AG
- Bio Products Laboratory Ltd
- Bioxodes SA
- Bristol-Myers Squibb Co
- Cambryn Biologics LLC
- China Resources Pharmaceutical Group Ltd
- eXithera Pharmaceuticals Inc
- Ionis Pharmaceuticals Inc
- Jiangsu Hengrui Medicine Co Ltd
- KLUS Pharma Inc
- Merck & Co Inc
- Mochida Pharmaceutical Co Ltd
- Novartis AG
- Ono Pharmaceutical Co Ltd
- Regeneron Pharmaceuticals Inc
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Sichuan Kelun Pharmaceutical Co Ltd
- Sirnaomics Ltd
- Suzhou Ribo Life Sciences Co Ltd
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Drug Profiles
- 7300 Series - Drug Profile
- Product Description
- Mechanism Of Action
- A-186 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- A-336 - Drug Profile
- Product Description
- Mechanism Of Action
- AB-023 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- abelacimab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- asundexian - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BMS-962212 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BMS-986209 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- coagulation factor XI (human) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- coagulation factor XI (human) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- coagulation factor XI (human) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- EP-7041 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- fesomersen sodium - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IONIS-FXIRx - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Ir-CPI - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KN-060 - Drug Profile
- Product Description
- Mechanism Of Action
- milvexian - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MK-2060 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MR-1007 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NIP-003 - Drug Profile
- Product Description
- Mechanism Of Action
- ONO-7684 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- osocimab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- REGN-9933 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SAL-0104 - Drug Profile
- Product Description
- Mechanism Of Action
- SHR-2285 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SKB-336 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Inhibit Coagulation Factor XI for Bleeding and Clotting Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Inhibit Factor XI for Bleeding And Clotting Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit Factor XIa for Arterial Thrombosis - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SR-059 - Drug Profile
- Product Description
- Mechanism Of Action
- STP-122G - Drug Profile
- Product Description
- Mechanism Of Action
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Dormant Products
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Discontinued Products
- Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Product Development Milestones
- Featured News & Press Releases
- Aug 28, 2022: Late-breaking results from phase 2 AXIOMATIC-SSP study of Milvexian, an investigational oral factor XIa inhibitor, show favorable antithrombotic profile in combination with dual antiplatelet therapy
- Aug 25, 2022: Anthos therapeutics launches second phase 3 clinical trial of its dual-acting Factor XI inhibitor, abelacimab
- Aug 23, 2022: Merck receives fast track designation from the U.S. FDA for MK-2060, an investigational anticoagulant therapy
- Aug 22, 2022: Bayer to present data from cardiovascular portfolio, including a late-breaking presentation from new phase IIb data from PACIFIC Trial program for the oral factor XIa Inhibitor asundexian
- Jul 29, 2022: Ionis reports positive Phase IIb data of fesomersen for thrombosis
- Jul 28, 2022: Phase 2b studies of investigational selective coagulation modulator osocimab in patients with advanced renal disease completed
- Jul 13, 2022: Four new sets of pre-clinical data further expands the evidence supporting abelacimab
- Jul 11, 2022: Anthos Therapeutics announces that abelacimab has received FDA fast track designation for the treatment of thrombosis associated with cancer
- Jun 13, 2022: Anthos Therapeutics to host discussion with global experts on the promise of Factor XI Inhibition at the 2022 BIO International Convention
- May 05, 2022: Abelacimab: first factor XI inhibitor to enroll patients in a phase 3 clinical trial
- Apr 11, 2022: Announcement of Haisco on obtaining the drug clinical trial approval notice for HSK36273
- Apr 03, 2022: Bayer presents positive results from first Phase 2b trial on safety of asundexian in patients with atrial fibrillation
- Mar 29, 2022: Bayer to present data on Asundexian at the American College of Cardiology's 71st Annual Scientific Session
- Feb 10, 2022: Bayer receives FDA Fast Track Designation for asundexian stroke program
- Jan 18, 2022: Haisco announces notice of acceptance for clinical trial application of HSK36273 for innovative drug injection
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Alphamab Oncology, 2022
- Pipeline by Anthos Therapeutics Inc, 2022
- Pipeline by Aronora Inc, 2022
- Pipeline by Bayer AG, 2022
- Pipeline by Bio Products Laboratory Ltd, 2022
- Pipeline by Bioxodes SA, 2022
- Pipeline by Bristol-Myers Squibb Co, 2022
- Pipeline by Cambryn Biologics LLC, 2022
- Pipeline by China Resources Pharmaceutical Group Ltd, 2022
- Pipeline by eXithera Pharmaceuticals Inc, 2022
- Pipeline by Ionis Pharmaceuticals Inc, 2022
- Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Pipeline by KLUS Pharma Inc, 2022
- Pipeline by Merck & Co Inc, 2022
- Pipeline by Mochida Pharmaceutical Co Ltd, 2022
- Pipeline by Novartis AG, 2022
- Pipeline by Ono Pharmaceutical Co Ltd, 2022
- Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, 2022
- Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, 2022
- Pipeline by Sirnaomics Ltd, 2022
- Pipeline by Suzhou Ribo Life Sciences Co Ltd, 2022
- Dormant Projects, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alphamab Oncology
- Anthos Therapeutics Inc
- Aronora Inc
- Bayer AG
- Bio Products Laboratory Ltd
- Bioxodes SA
- Bristol-Myers Squibb Co
- Cambryn Biologics LLC
- China Resources Pharmaceutical Group Ltd
- eXithera Pharmaceuticals Inc
- Ionis Pharmaceuticals Inc
- Jiangsu Hengrui Medicine Co Ltd
- KLUS Pharma Inc
- Merck & Co Inc
- Mochida Pharmaceutical Co Ltd
- Novartis AG
- Ono Pharmaceutical Co Ltd
- Regeneron Pharmaceuticals Inc
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Sichuan Kelun Pharmaceutical Co Ltd
- Sirnaomics Ltd
- Suzhou Ribo Life Sciences Co Ltd
